Author:
Dall’Era Maria,Chakravarty Eliza F.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. •• Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF to the B-cell receptor. Immunol Rev 2010, 237:205–25. This is a very detailed review of the role of BAFF in B-cell development, survival, and activation.
2. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.
3. Merrill JT, Newelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222–33.
4. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60:S429 [abstract 1149].
5. Terrier B, Amoura A, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity to Rituximab Registry. Arthritis Rheum. 2010;62:2458–66.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献